Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Bausch + Lomb has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.
Bausch + Lomb (NYSE:BLCO – Get Free Report) last issued its earnings results on Wednesday, February 21st. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.07. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Bausch + Lomb had a negative net margin of 6.27% and a positive return on equity of 3.70%. The firm’s revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 earnings per share. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Bausch + Lomb Stock Performance
NYSE:BLCO opened at $14.85 on Wednesday. The firm has a market capitalization of $5.22 billion, a PE ratio of -20.07, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.09. The business’s fifty day moving average price is $15.92 and its 200 day moving average price is $15.73. Bausch + Lomb has a 12 month low of $13.62 and a 12 month high of $21.95.
Wall Street Analyst Weigh In
View Our Latest Analysis on Bausch + Lomb
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Read More
- Five stocks we like better than Bausch + Lomb
- Investing in Construction Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Where to Find Earnings Call Transcripts
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Are Dividend Contenders? Investing in Dividend Contenders
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.